Navigation Links
The reason why antiviral therapy can't annihilate HIV infection, and what to do about it

Antiviral therapy has been used to suppress HIV replication and has dramatically improved the clinical course of disease in affected patients. But the existence of viral reservoirs precludes the complete elimination of HIV from treated patients. In a new study appearing on November 1 in The Journal of Clinical Investigation, Tae-Wook Chun and colleagues from the NIH offer new insight into the eradication of HIV in infected individuals receiving antiviral therapy.

The authors focused on HIV-infected patients who had received effective antiviral therapy for extended periods of time and examined the nature of their residual virus as well as the underlying mechanisms of viral persistence. They demonstrate that HIV persists in both resting and activated CD4+ T cells of patients having received up to 9.1 years of effective antiviral therapy with undetectable levels of HIV in their plasma.

Their data also suggest that latently infected, resting CD4+ T cells may become reactivated, most likely as a result of normal immunologic responses to various antigens and cytokines. In turn, virions released during the reactivation process may spread to neighboring resting as well as activated CD4+ T cells; direct cell-to-cell spread in the absence of virion release may also occur.

The study could impact the design of future therapies aimed at eradicating HIV in patients who have received effective antiviral therapy for extended periods of time. Considering that reactivation of latently infected, resting CD4+ T cells contributes to the persistence of HIV and initiation of new infection cycles, co-administration of an effective and safe reagent that is capable of dampening cellular activation could minimize the spread of virions to uninfected bystander cells.


'"/>

Source:Journal of Clinical Investigation


Page: 1

Related biology news :

1. Bobbing birds do it for a reason
2. A reason why video games are hard to give up
3. Leading reason for corneal transplants comes into focus
4. Novel antiviral technology inhibits RSV infection in mice
5. Biota makes major antiviral discovery
6. New possibilities for flu antiviral and vaccine research emerge from Spanish flu virus
7. Bird flu -- Call for antiviral drugs to be shared
8. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
9. Columbia research lifts major hurdle to gene therapy for cancer
10. Combination therapy boosts effectiveness of telomere-directed cancer cell death
11. Gene therapy converts dead bone graft to new, living tissue
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/30/2016)... , Nov. 30, 2016  higi SH ... new partnership initiative targeting national brands, industry thought-leaders ... reward their respective audiences for taking steps to ... its inception in 2012, higi has built the ... impacting over 38 million people who have conducted ...
(Date:11/28/2016)... Nov. 28, 2016 "The ... of 16.79%" The biometric system market is in ... in the near future. The biometric system market is ... 2022, at a CAGR of 16.79% between 2016 and ... of biometric technology in smartphones, rising use of biometric ...
(Date:11/21/2016)... 2016   Neurotechnology , a provider of ... announced that the MegaMatcher On Card fingerprint matching ... the NIST Minutiae Interoperability Exchange (MINEX) III ... steps of the evaluation protocol. ... of fingerprint templates used to establish compliance of ...
Breaking Biology News(10 mins):
(Date:12/6/2016)... ... December 06, 2016 , ... ... today announced it has acquired the assets of Theorem Clinical Research - ... focuses on clinical trial drug packaging, labeling, storage, reconciliation, and distribution for ...
(Date:12/6/2016)... SAN DIEGO , Dec. 6, 2016  Creative ... Santosh Kesari , MD, PhD, FANA, FAAN to the ... in neurology and clinical trials to assist the Company,s ... of stroke. The AmnioStem product is a universal donor stem ... therapeutic activity in animal models of stroke 1 .  ...
(Date:12/6/2016)... MENLO PARK, Calif. , Dec. 6, 2016 ... of up to $150 million from the National ... Infectious Diseases and the Division of AIDS (NIAID-DAIDS) ... microbicides and other non-vaccine pre-exposure (PreP) agents. Under ... suite of preclinical product development services for candidate ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... and development of precision treatments for neurodegenerative diseases, today announced the validated ... inhibited the direct neurotoxic effect of prion-like forms of Amyloid beta (Aß) ...
Breaking Biology Technology: